Investigational drug · Phase 3
simmitinib
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Oesophageal Squamous Cell Carcinoma, Advanced Solid Tumor, Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 24, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "simmitinib"
First trial start
2024
Jan 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "simmitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Oesophageal Squamous Cell Carcinoma
- Advanced Solid Tumor
- Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
- Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
- Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "simmitinib" as an intervention, largest first.
- A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell CarcinomaPivotal-lookingNot yet recruiting
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06656091 · 450 participants (planned) · Start Oct 31, 2024 · Primary completion Jan 30, 2027
Drug: simmitinib; investigator's choice of chemotherapy,include docetaxel or irinotecan. · For: Advanced Oesophageal Squamous Cell Carcinoma
- A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaPivotal-lookingNot yet recruiting
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06577376 · 252 participants (planned) · Start Aug 26, 2024 · Primary completion Aug 26, 2026
Drug: DP303c; Simmitinib tablets and 2 more · For: Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma; Expressing Human Epidermal Growth Factor Receptor-2 (HER-2); Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
- A Study of Simmitinib Plus SG001 in Advanced Solid TumorsNot yet recruiting
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06132217 · 168 participants (planned) · Start Jan 30, 2024 · Primary completion Jan 30, 2027
Drug: Simmitinib; SG001 · For: Advanced Solid Tumor
Sites: Beijing, China
- A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell CarcinomaPivotal-lookingStatus unknown
Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
NCT06512428 · 138 participants (planned) · Start Mar 15, 2024 · Primary completion Jan 30, 2026
Drug: simmitinib plus irinotecan liposome; irinotecan liposome and 1 more · For: Advanced Esophageal Squamous Cell Carcinoma
Sites: Heilongjiang, China
- A Phase I Trial of Simmitinib in Advanced Solid TumorsStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT04058587 · 50 participants (planned) · Start Jun 8, 2020 · Primary completion Jan 31, 2023
Drug: Simmitinib · For: Advanced Solid Tumor
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Oesophageal Squamous Cell Carcinoma
- include docetaxelPhase 31 trial
Shanghai Runshi Pharmaceutical Technology Co., Ltd · Advanced Oesophageal Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.